Unsere Studien

A Randomised, Double-blind, Chronic Dosing (56 week) Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab (MEDI-563) in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations
Status: recruiting

A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared with
tiotropium on Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with severe to very severe COPD.
Status: recruiting

BAL- Studie
"The development of nanoparticle protein corona from components of human bronchoalveloar lavage fluid: characterization and use in in vitro cell exposure systems highlighting the significance of nanoparticle exposures to those with inflammatory lung disorders, such as COPD, and pulmonary infections".
Status: recruiting

An exploratory, 12 week, randomised, partially double-blinded, placebo-controlled, parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed dose
combination or tiotropium (both delivered by the Respimat® inhaler), supervised exercise training and behaviour modification on exercise capacity and physical activity in patients with Chronic Obstructive
Pulmonary Disease (COPD)
Status: active, not recruiting

German COPD and Systemic Consequences - Comorbidities Net work
Status: active, not recruiting

FLAME - Studie
A 52-week treatment, multi-center, randomized, doubleblind, double dummy, parallel-group, active controlled
study to compare the effect of QVA149 (indacaterol maleate/ glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD
Status: active, not recruiting

A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease
Status: active, not recruiting

Efficacy and safety of Aclidinium/Formoterol Fumarate Fixed-Dose Combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease
Status: closed

NETs in COPD- Studie
Untersuchung der Bedeutung von neutrophilen Netzen bei COPD
Status: closed

REACT- Studie
Effect of roflumilast on exacerbation rate in patients with COPD treated with fixed combinations of LABA and ICS. A 52-week, randomised double-blind trial with roflumilast 500 μg versus placebo
Status: closed

SCOPE- Studie
Salzburg Chronic Obstructive Pulmonary disease- Exercise and Oxygen Study
Status: closed

SCOT Registry
Small Cell Lung Cancer registry to describe patient characteristics, treatment patterns and outcomes
Status: closed

TONADO- Studie
A randomized, double-blind, parallel group study to assess teh efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5μg / 5μg; 5μg/5μg) (delivered by Respimat® Inhaler) compared with teh individual components (2.5μg and 5μg tiotropium, 5μg olodaterol) (delivered by Respimat® Inhaler) in patients with chronic obstructive pulmonary disease‘
Status: closed

Randomized, double-blind, placebo-controlled, multicenter study comparing
ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis
Status: recruiting

A Randomized Phase 2 Study of AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib
Status: recruiting

A Randomized Phase 3 Study of LY2835219 plus Best Supportive Care versus Erlotinib plus Best Supportive Care in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Status: recruiting

A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and
Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, in Patients
receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung
Cancer (Stage IIIB – IV)
Status: recruiting

A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer
Status: active, not recruiting

A randomized, multicenter, double-blind, Phase 3 Trial comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in subjects with newly diagnosed extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
Status: active, not recruiting

Nivolumab I Studie
An Open-label Randomized Phase III Trial of BMS-936558 (Nivolumab) versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status: follow-up

Nivolumab II Studie
An Open-Label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small cell Lung Cancer (NSCLC)
Status: follow-up

Lung cancer Audit
The National Lung Cancer Audit Austria
Status: closed

LUX LUNG 8- Studie
A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum based chemotherapy
Status: closed

Marquee- Studie
A phase III, randomized, double-blinded, placebo-controlled study of ARQ197 plus Erlotinib versus placebo plus Erlotinib in previously treated subjects with locally advanced or metastatic, non-squamous, non-small-cell lung cancer (NSCLC)
Status: closed

EGFR- Studie
A Multi-center, Randomized, Double-blind, Placebo controlled, Phase III Study of Single-agent Tarceva (erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors
Status: closed

Idiopatic Lung Fibrosis
Pirfinidone Beobachtungsstudie
Post-Authorisations Safety Study (PASS) of Esbriet® (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting
Status: recruiting

Prifinidone- Studie
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone
Status: closed

Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft mbH | Müllner Hauptstraße 48 | A-5020 Salzburg
Telefon: +43 (0)5 7255-0 | Fax: +43 (0)5 7255-20199 | E-Mail: office@salk.at | © 2013-2016
Letzte Änderung: 20.09.2016 Impressum Datenschutz AGB
x schließen